Global pharmaceutical companies

Global pharmaceutical companies produce APIs captively and/or source advanced, exclusive PFCs from European fine-chemical companies. 

CSR operationalization is not a simple task a global pharmaceutical company may employ over 50,000 people in as many as 100 countries. To move this workforce spread across operating units of the firm throughout many diverse geographic markets requires a multi-year commitment of the corporate board to implement it. It is partially for this research that the industry s efforts to act more responsibly are largely unknown outside the firm. Added to this problem of visibility is that individual companies have little identity per se - their products may be known but very little corporate visibility exists with patients and other stakeholders. 

Howard, B. Experiences and expectations for transferring automated pharmaceutical analysis methods in a global pharmaceutical company. In Proceedings of the 1999 International Symposium on Laboratory Automation and Robotics, CD-ROM version, ISLAR, Hopkinton, MA, 1999. 

This shift in the source areas for discovery and technologies away from the big pharma corporations (integrated global pharmaceutical companies) necessitates the creation of R D networks and alliances to capture those innovations and bring them through the development phase to the patient and market. 

Today, no matter where the corporate offices of a global pharmaceutical company are, the value of the US, European and Japanese m ets must be considered in the overall valuation, though the pressures on revenues differ in each region. 

---